Amsterdam University Medical Centers

Researchers

• JGJonathan Garnier

Running trials

• Not yet recruiting

  Safety and Effectiveness Assessment of AneuFix Injectable Polymer Sac Filling to Assure Long-term Durability of EVAR.

  NCT07928505· TripleMed B.V.· Source

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· University of Oxford· Source

• Not yet recruiting

  PANVIRAL: Safety, Feasibility and Immunogenicity of Intra-Tumoral ORCA-010 Oncolytic Virus Administration in Metastatic Pancreatic Cancer – A Single-Center Phase 1 Trial

  2026-527268-33-00· Phase 1· Amsterdam UMC Stichting· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.

  NCT07480395· W.L.Gore & Associates· Source

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study - PROMOTE

  NCT07434973· Phase 3· University of Oxford· Source

• Not yet recruiting

  Splintless Versus Conventional Maxillomandibular Advancement Surgery for Obstructive Sleep Apnea

  NCT07598461· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Not yet recruiting

  A research study to evaluate how well etavopivat works in children with sickle cell disease

  2025-524464-38-00· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis

  2026-526348-11-01· Phase 4· Amsterdam UMC Stichting· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

  2026-526167-38-00· Phase 4· Amsterdam UMC Stichting· Source

• Not yet recruiting

  Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)

  NCT07799298· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Not yet recruiting

  AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery

  NCT07883551· Catharina Ziekenhuis Eindhoven· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial

  NCT07872020· Erasmus Medical Center· Source

• Not yet recruiting

  Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

  NCT07401901· Medtronic MiniMed, Inc.· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· University of Oxford· Source

• Not yet recruiting

  Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

  2025-521143-20-00· Phase 1· Amsterdam UMC Stichting· Source

• Not yet recruiting

  Brain Immuno-PET

  2026-525254-10-00· Phase 1· Amsterdam UMC Stichting· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  MDMA-assisted therapy for adolescents with treatment-resistant PTSD

  2024-515184-65-01· Phase 2· Stichting Amsterdam UMC· Source

• Not yet recruiting

  A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)

  2025-524555-31-00· Phase 1· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Not yet recruiting

  Closed-Loop Therapeutic Refinement Using Local Field Potentials in Parkinson's Disease

  NCT07105280· HagaZiekenhuis· Source

• Not yet recruiting

  NutrImmune: Precision Nutrition to Improve Immunity in Individuals With Obesity

  NCT07850206· Institut National de la Santé Et de la Recherche Médicale, France· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

  NCT07775924· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational Study

  NCT07924371· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).

  2026-525260-18-00· Phase 2· Amsterdam UMC Stichting· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

  2024-520052-19-04· Phase 1/2· Amsterdam UMC Stichting· Source

• Not yet recruiting

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Servier· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

  NCT07699380· Phase 2· University of Washington· Source

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Amsterdam UMC, location VUmc· Source

• Recruiting

  A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

  NCT07630714· Phase 2· AstraZeneca· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Alnylam Pharmaceuticals· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  Timing of Immunotherapy in Melanoma

  NCT07696715· Radboud University Medical Center· Source

• Recruiting

  Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases

  2025-522834-30-01· Phase 2· Amsterdam UMC Stichting· Source

• Recruiting

  Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

  2025-524129-42-00· Phase 4· Amsterdam UMC Stichting· Source

Showing 50 of 522.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer20 recruiting
• Colorectal cancer18 recruiting
• Gastric and oesophageal cancer18 recruiting
• Lung cancer17 recruiting
• Crohn's disease16 recruiting
• Coronary artery disease15 recruiting
• Multiple myeloma15 recruiting
• High blood pressure14 recruiting
• Liver and biliary tract cancer14 recruiting
• Childhood cancers9 recruiting
• Fatty liver disease (MASLD/MASH)9 recruiting
• Prostate cancer9 recruiting
• Stroke8 recruiting
• Alzheimer disease7 recruiting
• Aortic aneurysm7 recruiting
• Bladder cancer7 recruiting
• Ovarian cancer7 recruiting
• Type 2 diabetes7 recruiting
• Acute myeloid leukaemia6 recruiting
• Atrial fibrillation6 recruiting
• Dilated cardiomyopathy6 recruiting
• Melanoma6 recruiting
• Parkinson disease6 recruiting
• Pulmonary arterial hypertension6 recruiting
• Cervical cancer5 recruiting
• Chronic kidney disease5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Glioblastoma5 recruiting
• Heart failure5 recruiting
• Long COVID and ME/CFS5 recruiting
• Lupus (SLE)5 recruiting
• Multiple sclerosis5 recruiting
• Sickle cell disease5 recruiting
• Ulcerative colitis5 recruiting
• Aortic stenosis4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)4 recruiting
• Familial hypercholesterolaemia4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Liver cirrhosis4 recruiting
• Myelodysplastic syndromes4 recruiting
• Obesity4 recruiting
• Rheumatoid arthritis4 recruiting
• Type 1 diabetes4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Amyloidosis3 recruiting
• Ankylosing spondylitis3 recruiting
• Asthma3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Endometrial cancer3 recruiting
• Eosinophilic oesophagitis3 recruiting
• Frontotemporal dementia3 recruiting
• Haemophilia3 recruiting
• Head and neck cancer3 recruiting
• HIV3 recruiting
• Neuroendocrine tumours3 recruiting
• Schizophrenia3 recruiting
• Triple-negative breast cancer3 recruiting
• Ventricular tachycardia3 recruiting
• Vitiligo3 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Barrett's oesophagus2 recruiting
• Cerebral palsy2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Chronic rhinosinusitis with nasal polyps2 recruiting
• Chronic spontaneous urticaria2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Hidradenitis suppurativa2 recruiting
• Hodgkin lymphoma2 recruiting
• Kidney cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Metastatic breast cancer2 recruiting
• Mild cognitive impairment2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obstructive sleep apnoea2 recruiting
• Peripheral artery disease2 recruiting
• Psoriasis2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• ALS (motor neurone disease)1 recruiting
• ANCA-associated vasculitis1 recruiting
• Brain metastases1 recruiting
• Bronchiectasis1 recruiting
• Coeliac disease1 recruiting
• Congenital heart disease1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Depression1 recruiting
• Diabetic foot ulcer1 recruiting
• Down syndrome1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Gaucher disease1 recruiting
• Haemophagocytic lymphohistiocytosis1 recruiting
• Hepatitis B1 recruiting
• Hypothyroidism1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lichen planus1 recruiting
• Polycystic ovary syndrome1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Sjögren's disease1 recruiting
• Testicular cancer1 recruiting
• Uterine fibroids1 recruiting

Closed trials

• Completed

  The RJVA-001 First in Human Trial in Adults with Inadequately Controlled Type 2 Diabetes.

  2025-524438-24-00· Phase 1/2· Fractyl Health Inc.· Source

• Active, not recruiting

  An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT07424144· Phase 3· Sanofi· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

  NCT07118449· Phase 2· XyloCor Therapeutics, Inc.· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Biomx Ltd.· Source

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Citryll BV· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  Effect of Agricultural Practices on Crops, Gut Microbiome, and Human Health

  NCT07165145· Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

  2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source

• Active, not recruiting

  Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

  NCT06716814· Phase 3· Swedish Orphan Biovitrum· Source

• Completed

  Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide

  NCT07819227· Phase 2· University Medical Center Groningen· Source

• Recruiting

  3TR-PARTNER-RA

  2024-511470-79-00· Phase 4· Queen Mary University Of London· Source

• Completed

  The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris

  NCT06415227· Phase 2· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT06834360· Phase 3· Sanofi· Source

• Completed

  A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer

  2024-515218-42-00· Phase 1· GE Healthcare Limited· Source

• Completed

  ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial

  2024-511711-21-00· Phase 4· Amsterdam UMC Stichting· Source

• Active, not recruiting

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· Phase 3· Arcus Biosciences, Inc.· Source

• Completed

  GENPAD

  NCT04619927· Phase 4· Radboud universitair medisch centrum Stichting· Source

• Active, not recruiting

  A trial to learn how safe AZD7798 is and how well it works in adults with ileal Crohn’s disease who have an ileostomy

  2024-514407-33-00· Phase 2· AstraZeneca AB· Source

• Completed

  Synaptic density and tau pathology in Alzheimer’s disease

  2024-517636-22-00· Phase 2· Amsterdam UMC Stichting· Source

• Completed

  A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

  2023-509900-14-00· Phase 1· F. Hoffmann-La Roche AG· Source

• Completed

  Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS

  NCT06426134· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Recruiting

  Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

  NCT06457789· Phase 2/3· Amsterdam UMC, location VUmc· Source

• Completed

  DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

  2024-518985-29-02· Phase 1/2· Amsterdam UMC Stichting· Source

• Completed

  PARADOX study

  2024-515278-28-00· Phase 4· Stichting Amsterdam UMC· Source

• Completed

  Memory Enhancement Using Transcranial Alternating Current Stimulation

  NCT06202872· Amsterdam UMC, location VUmc· Source

• Completed

  A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

  2024-516511-24-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

  NCT06598462· Phase 2· Uniquity One (UNI)· Source

• Completed

  ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer

  NCT06095674· Phase 1· Amsterdam UMC· Source

• Completed

  A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study

  2023-509460-19-00· Phase 1/2· Amsterdam UMC· Source

• Completed

  Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression

  NCT05415397· Phase 3· Amsterdam UMC Stichting· Source

• Completed

  THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

  2024-516260-29-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Completed

  Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial

  2024-516057-42-00· Phase 2· Stichting Amsterdam UMC· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  HepBTer: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients

  2024-514888-25-00· Phase 2· Stichting Amsterdam UMC· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat)

  NCT06240520· Phase 2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

  NCT06333860· Phase 4· AbbVie· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

  NCT05865886· Phase 2· Boehringer Ingelheim· Source

• Completed

  MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY)

  NCT06308549· Maartje de Wit· Source

• Completed

  Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study

  2023-507907-73-00· Phase 4· Amsterdam UMC· Source

Showing 50 of 182.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease274 works · 13 trials
• Stroke236 works · 17 trials
• Heart failure193 works · 14 trials
• Obesity176 works · 10 trials
• Atrial fibrillation125 works · 12 trials
• Type 2 diabetes123 works · 15 trials
• HIV123 works · 6 trials
• Crohn's disease107 works · 30 trials
• Multiple sclerosis94 works · 11 trials
• Lung cancer93 works · 41 trials
• Colorectal cancer90 works · 28 trials
• Chronic kidney disease81 works · 13 trials
• Parkinson disease78 works · 6 trials
• Coronary artery disease78 works · 32 trials
• Ulcerative colitis67 works · 23 trials
• Depression64 works · 3 trials
• Multiple myeloma63 works · 35 trials
• Pancreatic cancer62 works · 26 trials
• Prostate cancer58 works · 17 trials
• Mild cognitive impairment58 works · 4 trials
• Tuberculosis54 works · 0 trials
• Schizophrenia54 works · 5 trials
• Rheumatoid arthritis54 works · 6 trials
• Asthma51 works · 4 trials
• Deep vein thrombosis and pulmonary embolism49 works · 4 trials
• Gastric and oesophageal cancer46 works · 23 trials
• Aortic aneurysm45 works · 10 trials
• Fatty liver disease (MASLD/MASH)38 works · 12 trials
• Lewy body dementia38 works · 0 trials
• Osteoarthritis38 works · 0 trials